Author

M. Tsoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. S. Ziegler· 2 shared R. Firestein· 2 shared A. Ehteda· 1 shared A. Gopalakrishnan· 1 shared A. Khan· 1 shared A. Lee· 1 shared A. M. Douglas· 1 shared A. Mannan· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. S. Ziegler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma

H. Holliday, A. Khan, A. Ehteda, H. Nguyen, S. E. Ross, N. Jayatilleke, A. Gopalakrishnan, E. Wang, Y. Colino Sanguino, D. Kavanagh, X. Guo, J. Liu, D. Lawrence, C. X. Sun, R. Lehmann, , D. S. Ziegler

This study shows that combining FACT and BET inhibition disrupts oncogenic transcription and extends survival in Diffuse Midline Glioma models.

bioRxiv · Jun 6, 2024 · PreprintCancer Biology

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

R. J. Duchatel, E. R. Jackson, S. G. Parackal, C. Sun, P. Daniel, A. Mannan, I. J. Findlay, D. Staudt, Z. P. Germon, S. Laternser, D. Kiltschewskij, P. S. Kearney, M. F. B. Jamaluddin, A. M. Douglas, T. Beitaki, , M. D. Dun

This study identifies PI3K/mTOR as a targetable genetic dependency in DIPG and demonstrates that combining paxalisib with metformin improves survival in xenograft models.

bioRxiv · Apr 17, 2023Cancer Biology

Copper chelation inhibits TGF-β pathways and suppresses epithelial-mesenchymal transition in cancer

E. M. Poursani, D. Mercatelli, P. Raninga, J. L. Bell, F. Saletta, F. V. Kohane, Y. Zheng, J. Rouaen, T. R. Jue, F. T. Michniewicz, E. Kasiou, M. Tsoli, G. Cirillo, S. Waters, T. Shai-Hee, , O. VITTORIO

This paper shows copper chelation inhibits TGF-β pathways and reduces EMT in cancer cells, potentially offering a new therapeutic strategy for targeting TGF-β in cancer.

bioRxiv · Oct 3, 2022 · PreprintCancer Biology